Sunshine Biopharma Inc.: 10-Q filed 2017-11-15

Name: Sunshine Biopharma Inc.: 10-Q filed 2017-11-15
Creator: Sunshine Biopharma Inc.

What Sunshine Biopharma Inc. reported in its quarterly report filed 2017-11-15 (fiscal Q3 2017): 28 published measures, 74 facts as tagged in accession 0001654954-17-010704.

This filing

Form: 10-Q (quarterly report)
Filed: 2017-11-15
Fiscal period: fiscal Q3 2017
Accession: 0001654954-17-010704 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Sunshine Biopharma Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2017-09-30	256,000	USD
At 2016-12-31	64,404	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2017-09-30	609,865	USD
At 2016-12-31	274,104	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2017-09-30	-353,865	USD
At 2016-12-31	-209,700	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2017-09-30	188,086	USD
At 2016-12-31	57,453	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-147,611	USD	92
2017-01-01 to 2017-09-30	-828,757	USD	273
2016-07-01 to 2016-09-30	-1,585,620	USD	92
2016-01-01 to 2016-09-30	-2,372,224	USD	274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	-334,038	USD	273
2016-01-01 to 2016-09-30	-282,988	USD	274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	456,541	USD	273
2016-01-01 to 2016-09-30	255,293	USD	274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	0	USD	273
2016-01-01 to 2016-09-30	-2,343	USD	274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2017-09-30	-13,406,712	USD
At 2016-12-31	-12,577,954	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	907,729,815	shares	92
2017-01-01 to 2017-09-30	857,166,626	shares	273
2016-07-01 to 2016-09-30	262,370,859	shares	92
2016-01-01 to 2016-09-30	238,983,449	shares	274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	0	USD/shares	92
2017-01-01 to 2017-09-30	0	USD/shares	273
2016-07-01 to 2016-09-30	-0.01	USD/shares	92
2016-01-01 to 2016-09-30	-0.01	USD/shares	274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2017-09-30	58,094	USD
At 2016-12-31	5,944	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-113,805	USD	92
2017-01-01 to 2017-09-30	-695,013	USD	273
2016-07-01 to 2016-09-30	-116,016	USD	92
2016-01-01 to 2016-09-30	-657,011	USD	274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2017-09-30	197,906	USD
At 2016-12-31	58,460	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	27,427	USD	92
2017-01-01 to 2017-09-30	46,169	USD	273
2016-07-01 to 2016-09-30	12,129	USD	92
2016-01-01 to 2016-09-30	29,080	USD	274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2017-09-30	609,865	USD
At 2016-12-31	274,104	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2017-09-30	12,105	USD
At 2016-12-31	28,122	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	0	USD	92
2017-01-01 to 2017-09-30	0	USD	273
2016-07-01 to 2016-09-30	0	USD	92
2016-01-01 to 2016-09-30	32,793	USD	274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2017-09-30	918,736,498	shares
At 2016-12-31	769,399,858	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2017-09-30	12,075,586	USD
At 2016-12-31	11,548,460	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2017-09-30	8,524	USD
At 2016-12-31	394	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2017-09-30	7,362	USD
At 2016-12-31	2,272	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-143,276	USD	92
2017-01-01 to 2017-09-30	-820,627	USD	273
2016-07-01 to 2016-09-30	-1,585,925	USD	92
2016-01-01 to 2016-09-30	-2,371,195	USD	274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	113,805	USD	92
2017-01-01 to 2017-09-30	695,013	USD	273
2016-07-01 to 2016-09-30	116,016	USD	92
2016-01-01 to 2016-09-30	657,011	USD	274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-33,806	USD	92
2017-01-01 to 2017-09-30	-133,744	USD	273
2016-07-01 to 2016-09-30	-1,469,604	USD	92
2016-01-01 to 2016-09-30	-1,715,213	USD	274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	3,537	USD	273
2016-01-01 to 2016-09-30	0	USD	274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	63,912	USD	273
2016-01-01 to 2016-09-30	104,128	USD	274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	-16,326	USD	273
2016-01-01 to 2016-09-30	-107,799	USD	274

Inspect the source

Entity: Sunshine Biopharma Inc. / CIK 0001402328
Captured: 2026-09-20T08:00:47.083Z
SEC response SHA-256: 089eb69bd01c2bc993f5073ccdb651eba31ddb7f7ea640d657095dcd4ddd9932

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001402328.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))